公开(公告)号：WO2011011882A1

公开(公告)日：2011-02-03

申请号：PCT/CA2010/001179

申请日：2010-07-29

Applicant: PHENOMENOME DISCOVERIES INC. ,  RITCHIE, Shawn ,  GOODENOWE, Dayan ,  KHAN, M. Amin ,  AHIAHONU, Pearson W. K.

Inventor： RITCHIE, Shawn ,  GOODENOWE, Dayan ,  KHAN, M. Amin ,  AHIAHONU, Pearson W. K.

IPC: C07C59/42 ,  A61K31/202 ,  A61P29/00 ,  A61P35/00 ,  C07C33/044 ,  C07C51/00 ,  C07C69/606 ,  C07C69/65 ,  C07C69/732 ,  C07F7/18 ,  G01N33/50

CPC classification number: A61K31/202 ,  C07C33/048 ,  C07C59/42 ,  C07C67/303 ,  C07C67/347 ,  C07C69/606 ,  C07C69/65 ,  C07C69/732 ,  G01N33/57407 ,  G01N33/57419 ,  G01N33/6893 ,  G01N2800/24 ,  A61K2300/00

Abstract: A compound of formula (I): wherein R represents a hydroxy substituted C 24 - C 40 straight chain aliphatic group containing at least one double bond in the carbon chain; and at least one carbon in the chain is substituted with a hydroxy group. Such compounds are useful for detecting inflammation, inflammatory disorders and cancer in a subject, and can also be used in therapeutic applications including treatment and/or prevention of these conditions. Pharmaceutical compositions, combinations and supplements, as well as methods of treatment using the described compounds are therefore also described.

Abstract translation: 式（I）的化合物：其中R表示在碳链中含有至少一个双键的羟基取代的C 24 -C 40直链脂族基团; 并且链中的至少一个碳被羟基取代。 这样的化合物可用于检测受试者中的炎症，炎性疾病和癌症，并且还可用于治疗应用，包括治疗和/或预防这些病症。 因此，还描述了药物组合物，组合和补充剂以及使用所述化合物的治疗方法。

公开(公告)号：WO2010071988A1

公开(公告)日：2010-07-01

申请号：PCT/CA2009/001853

申请日：2009-12-18

Applicant: PHENOMENOME DISCOVERIES INC. ,  KHAN, Amin, M. ,  WOOD, Paul, L. ,  GOODENOWE, Dayan ,  MANKIDY, Rishikesh ,  AHIAHONU, Pearson

Inventor： KHAN, Amin, M. ,  WOOD, Paul, L. ,  GOODENOWE, Dayan ,  MANKIDY, Rishikesh ,  AHIAHONU, Pearson

IPC: C07D339/04 ,  A61K31/232 ,  A61K31/385 ,  C07C227/02 ,  C07C229/22 ,  C07C319/02 ,  C07C323/59

CPC classification number: C07C323/59 ,  C07C229/22 ,  C07C279/14 ,  C07D339/04 ,  C07F9/106

Abstract: Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).

Abstract translation: 本文描述的是式I的1-烷基，2-酰基甘油衍生物的合成途径和治疗用途：当向哺乳动物生物系统施用时，其导致独特于醚脂质合成能力的特异性sn-2取代的乙醇胺plasmalogen的细胞浓度增加 的系统。 以这种方式提高特定sn-2取代物种的水平可能导致膜胆固醇水平的降低和淀粉样蛋白分泌的降低。 这些化合物可用于治疗或预防与增加的膜胆固醇，增加的淀粉样蛋白相关的老化疾病和降低的血浆素水平，例如神经变性（包括阿尔茨海默病，帕金森病和年龄相关性黄斑变性），认知障碍，痴呆 ，癌症（例如前列腺癌，肺癌，乳腺癌，卵巢癌和肾癌），骨质疏松症，双相性精神障碍和血管疾病（如动脉粥样硬化，高胆固醇血症）。

公开(公告)号：WO2009012595A1

公开(公告)日：2009-01-29

申请号：PCT/CA2008/001366

申请日：2008-07-25

Applicant: PHENOMENOME DISCOVERIES INC. ,  GOODENOWE, Dayan

Inventor： GOODENOWE, Dayan

IPC: G01N33/48 ,  G01N33/483 ,  G01N33/49 ,  G01N33/92

CPC classification number: G01N33/6848 ,  G01N33/6893 ,  G01N33/92 ,  G01N2405/00 ,  G01N2405/04 ,  G01N2800/30 ,  G01N2800/38 ,  Y10T436/24

Abstract: Methods for the diagnosis, risk assessment, and monitoring of Autism Spectrum Disorder (ASD) are disclosed. More specifically the present invention relates to the measurement of small molecules (metabolites) in human plasma that are found to have different abundances between persons with a clinical manifestation of ASD and subjects not expressing symptoms of ASD. Further, this invention relates to the monitoring of putative therapeutic strategies designed to ameliorate the biochemical abnormalities associated with ASD.

Abstract translation: 披露了自闭症谱系障碍（ASD）的诊断，风险评估和监测方法。 更具体地说，本发明涉及人类血浆中的小分子（代谢物）的测量，其发现具有ASD的临床表现的人与未表达ASD的症状的受试者之间具有不同的丰度。 此外，本发明涉及监测旨在改善与ASD相关的生化异常的推定治疗策略。

公开(公告)号：WO2008124916A1

公开(公告)日：2008-10-23

申请号：PCT/CA2008/000659

申请日：2008-04-09

Applicant: PHENOMENOME DISCOVERIES INC. ,  GOODENOWE, Dayan

Inventor： GOODENOWE, Dayan

IPC: G01N33/48 ,  G01N33/483

CPC classification number: G01N33/49 ,  G01N33/57484 ,  G01N33/6896 ,  G01N33/92 ,  G01N2560/00 ,  G01N2800/50 ,  G01N2800/7042 ,  H01J49/0031 ,  H01J49/38

Abstract: The present invention relates to methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging. The present invention describes the relationship between plasmalogen biosynthesis dysfunction and the biochemical and clinical manifestations of age related disorders. Specifically the present invention describes an increased prevalence of colon cancer, prostate cancer, lung cancer, breast cancer, ovary cancer, kidney cancer, cognitive impairment and dementia in subjects suffering from adult onset plasmalogen biosynthesis disorder (AO-PBD).

Abstract translation: 本发明涉及用于诊断和评估缺血性贫血的老化疾病的方法。 本发明描述了质膜生物合成功能障碍与年龄相关疾病的生化和临床表现之间的关系。 具体地说，本发明描述了患有成人起始型血浆原生质合成障碍（AO-PBD）的受试者中结肠癌，前列腺癌，肺癌，乳腺癌，卵巢癌，肾癌，认知障碍和痴呆症的患病率增加。

公开(公告)号：WO2007098585A1

公开(公告)日：2007-09-07

申请号：PCT/CA2007/000313

申请日：2007-02-28

Applicant: PHENOMENOME DISCOVERIES INC. ,  COOK, Lisa ,  GOODENOWE, Dayan

Inventor： COOK, Lisa ,  GOODENOWE, Dayan

IPC: C07F9/09 ,  G01N27/00 ,  G01N33/483 ,  G01N37/00

CPC classification number: G06F19/34 ,  C07F9/10 ,  C07F9/106 ,  G01N30/7233 ,  G01N33/6896 ,  G01N2800/2814 ,  G01N2800/2821 ,  G01N2800/50 ,  G01N2800/52 ,  Y10T436/163333

Abstract: The present invention is directed to a method for differentially diagnosing dementia or the risk of dementia in a patient. The method comprises obtaining a sample from the patient; analyzing the sample to obtain quantifying data for one or more than one metabolite marker; comparing the quantifying data for the one or more than one metabolite marker to corresponding data obtained from one or more than one reference sample; and using the comparison to differentially diagnose dementia or the risk of dementia. The method may also assis in assessing dementia or the risk of dementia in a patient. The present invention is also directed to metabolite markers and compounds useful in the present method.

Abstract translation: 本发明涉及用于差异诊断患者痴呆或痴呆风险的方法。 该方法包括从患者获得样品; 分析样品以获得一种或多于一种代谢标记物的量化数据; 将一种或多于一种代谢标记物的量化数据与从一种或多于一种参考样品获得的相应数据进行比较; 并使用比较来差异诊断痴呆或痴呆的风险。 该方法还可以帮助评估患者的痴呆或痴呆风险。 本发明还涉及可用于本发明方法的代谢物标记物和化合物。

公开(公告)号：WO2007030928A3

公开(公告)日：2007-03-22

申请号：PCT/CA2006/001502

申请日：2006-09-12

Applicant: PHENOMENOME DISCOVERIES INC. ,  RITCHIE, Shawn ,  GOODENOWE, Dayan

Inventor： RITCHIE, Shawn ,  GOODENOWE, Dayan

IPC: G01N33/574 ,  G01N33/53 ,  G01N33/50

Abstract: The present invention relates to the diagnosis of colorectal and ovarian cancers (CRC and OC, respectively). The present invention describes the relationship between endogenous small molecules and CRC or OC. Specifically, the present invention relates to the diagnosis of CRC and OC through the measurement of vitamin E isoforms and related metabolites. The present invention also relates to diagnostic markers identified in said method. The present invention relates to the underlying case and pre-symptomatic phases of CRC, the diagnosis of various stages and severity of CRC, the early detection of CRC, monitoring and diagnosing the effect of therapy on CRC and OC health states.

公开(公告)号：WO2008095275A1

公开(公告)日：2008-08-14

申请号：PCT/CA2007/001472

申请日：2007-08-27

Applicant: PHENOMENOME DISCOVERIES INC. ,  GOODENOWE, Dayan

Inventor： GOODENOWE, Dayan

IPC: A61K31/232 ,  A61P25/28 ,  A61P3/06

CPC classification number: A61K31/232 ,  A61K31/661 ,  A61K31/6615

Abstract: The present invention relates to the diagnosis, risk assessment, prevention, and treatment of Senile Dementia of the Alzheimer's Type (SDAT). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum. Subsets of these molecules are significantly altered in subjects with pathologically confirmed deposits of β-amyloid versus subjects without β-amyloid deposits and in subjects with a clinical manifestation of dementia consistent with a diagnosis of SDAT versus non-demented controls. Further, the invention relates to the diagnosis of various stages of SDAT, the early detection and prevention of SDAT symptoms, the treatment of SDAT, the differential diagnosis of non-SDAT dementia, and the identification of molecular targets for which chemical or biological treatments can be designed for the therapeutic intervention of SDAT. The present invention also relates to methods of using a molecular diagnostic assay to direct and select the appropriate therapeutic intervention for subjects suffering from dementia. The present invention also relates to small molecules or metabolites that are found to have significantly different abundances between persons with a clinical manifestation of SDAT and normal, non-demented patients.

Abstract translation: 本发明涉及老年痴呆型老年痴呆症（SDAT）的诊断，风险评估，预防和治疗。 更具体地说，本发明涉及人血清中乙醇胺磷脂的测定。 这些分子的亚群在病理证实的β-淀粉样蛋白沉积物与没有β-淀粉样蛋白沉积物的受试者和具有与SDAT与非痴呆对照的诊断一致的痴呆临床表现的受试者中显着改变。 此外，本发明涉及SDAT的各个阶段的诊断，SDAT症状的早期检测和预防，SDAT的治疗，非SDAT痴呆的鉴别诊断以及化学或生物治疗可以分析的分子靶标的鉴定 设计用于SDAT的治疗干预。 本发明还涉及使用分子诊断测定法来指导和选择患有痴呆症的受试者的适当治疗干预的方法。 本发明还涉及发现具有SDAT和正常非痴呆患者的临床表现的人之间具有显着不同丰度的小分子或代谢物。

公开(公告)号：WO2007030948A1

公开(公告)日：2007-03-22

申请号：PCT/CA2006/001530

申请日：2006-09-15

Applicant: PHENOMENOME DISCOVERIES INC. ,  GOODENOWE, Dayan

Inventor： GOODENOWE, Dayan

IPC: H01J49/26 ,  H01J49/14 ,  H01J49/40 ,  H01J49/42

CPC classification number: H01J49/38 ,  H01J49/0031 ,  H01J49/421

Abstract: A novel method and apparatus for Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (FTICR-MS). The FTICR-MS apparatus has a pre-ICR mass separation and filtering device capable of receiving ionized molecules with a plurality of mass to charge (M/Z) sub-ranges. The pre-ICR mass separation and filtering device divides the ionized molecules into a plurality of smaller packets, each of the smaller packets is within one of the M/Z sub-ranges. A magnet in the FTICR-MS apparatus provides a controlled magnetic field. A plurality of ion cyclotron resonance (ICR) cells are arranged in series in the controlled magnetic field and operate independently. An ion trapping device connects the pre-ICR mass separation and filtering device, and stores one of the plurality of smaller packets, prior to sending it to one of the plurality of ICR cells.

Abstract translation: 傅立叶变换离子回旋共振质谱（FTICR-MS）的新颖方法和装置。 FTICR-MS装置具有能够接收具有多个质量（M / Z）子范围的离子化分子的前ICR质量分离和过滤装置。 前ICR质量分离和过滤装置将电离分子分成多个较小的分组，每个较小的分组在M / Z子范围之一内。 FTICR-MS装置中的磁体提供受控的磁场。 多个离子回旋共振（ICR）单元在受控磁场中串联布置并独立运行。 离子捕获装置将ICR前质量分离和过滤装置连接，并且在将其发送到多个ICR单元之一之前存储多个较小分组之一。

公开(公告)号：WO2003081506A3

公开(公告)日：2003-10-02

申请号：PCT/CA2003/000389

申请日：2003-03-20

Applicant: PHENOMENOME DISCOVERIES INC. ,  HEATH, Douglas ,  GOODENOWE, Dayan

Inventor： HEATH, Douglas ,  GOODENOWE, Dayan

IPC: G06T11/20

Abstract: The invention can be summarized as follows. The present invention provides a method of displaying spectroscopic data comprising the steps of, i)obtaining spectroscopic data from a plurality of samples, each sample comprising one or more components wherein each component is characterized by an ordered pair (X,Y) of data comprising data element value X and data element value Y, wherein X is a data element value, equivalent or directly proportional to the mass of the component, and Y is a data element value equivalent or directly proportional to the amount of the component; ii) identifying all unique components comprising a common data element value X in said samples; computing the average of all X therefrom; and determining the average and optionally, the standard deviation for all Y values from all ordered data pairs comprising a common X; iii) generating a data structure comprising an array of codable cells, each cell assigned a color or other identifiable characteristic based on the relationship of the amount of each unique component present in each of said samples in relation to a predetermined value or other characteristic of the spectroscopic data. Also disclosed are data structures comprising spectroscopic data.

公开(公告)号：WO2003081506A2

公开(公告)日：2003-10-02

申请号：PCT/CA2003/000389

申请日：2003-03-20

Applicant: PHENOMENOME DISCOVERIES INC. ,  HEATH, Douglas ,  GOODENOWE, Dayan

Inventor： HEATH, Douglas ,  GOODENOWE, Dayan

IPC: G06F19/00

CPC classification number: G06T11/206 ,  G06F19/26 ,  G06F19/28 ,  G06F19/708 ,  H01J49/0036 ,  H01J49/38

Abstract: The invention can be summarized as follows. The present invention provides a method of displaying spectroscopic data comprising the steps of, i)obtaining spectroscopic data from a plurality of samples, each sample comprising one or more components wherein each component is characterized by an ordered pair (X,Y) of data comprising data element value X and data element value Y, wherein X is a data element value, equivalent or directly proportional to the mass of the component, and Y is a data element value equivalent or directly proportional to the amount of the component; ii) identifying all unique components comprising a common data element value X in said samples; computing the average of all X therefrom; and determining the average and optionally, the standard deviation for all Y values from all ordered data pairs comprising a common X; iii) generating a data structure comprising an array of codable cells, each cell assigned a color or other identifiable characteristic based on the relationship of the amount of each unique component present in each of said samples in relation to a predetermined value or other characteristic of the spectroscopic data. Also disclosed are data structures comprising spectroscopic data.

Abstract translation: 本发明可概括如下。 本发明提供一种显示光谱数据的方法，包括以下步骤：i）从多个样本获得光谱数据，每个样本包括一个或多个分量，其中每个分量的特征在于数据的有序对（X，Y），包括 数据元素值X和数据元素值Y，其中X是与分量的质量相当或直接成比例的数据元素值，Y是与分量的量相当或直接成比例的数据元素值; ii）识别包括所述样本中的公共数据元素值X的所有唯一分量; 计算所有X的平均值; 以及从包括公共X的所有有序数据对中确定所有Y值的平均值和可选地的标准偏差; iii）生成包括可编码单元阵列的数据结构，每个单元基于存在于每个所述样本中的每个唯一分量的量与预定值或其他特征的相关性分配颜色或其他可识别特征 光谱数据。 还公开了包括光谱数据的数据结构。